oxymatrine has been researched along with Body Weight in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, S; Huang, W; Li, Y; Ren, L; Song, G; Wang, Y; Yang, L; Zhang, H | 1 |
| Hu, Z; Shi, L; Song, G; Wang, C; Zhang, D; Zhang, H | 1 |
| Hu, ZJ; Shi, L; Shi, LJ; Song, GY; Wang, C; Zhang, DH; Zhang, HF | 1 |
| Jia, JP; Wang, SB | 1 |
4 other study(ies) available for oxymatrine and Body Weight
| Article | Year |
|---|---|
Oxymatrine alleviated hepatic lipid metabolism via regulating miR-182 in non-alcoholic fatty liver disease.
Topics: Alkaloids; Animals; Body Weight; Diet, High-Fat; Gene Knockdown Techniques; Hep G2 Cells; Humans; Insulin Resistance; Lipid Metabolism; Liver; Male; MicroRNAs; Non-alcoholic Fatty Liver Disease; Palmitic Acid; Quinolizines; Rats; Rats, Wistar | 2020 |
Oxymatrine ameliorates non-alcoholic fatty liver disease in rats through peroxisome proliferator-activated receptor-α activation.
Topics: Alkaloids; Animals; Body Weight; Disease Models, Animal; Fatty Liver; Insulin Resistance; Intra-Abdominal Fat; Lipid Metabolism; Lipids; Liver; Male; Non-alcoholic Fatty Liver Disease; Organ Size; PPAR alpha; Quinolizines; Rats | 2013 |
Oxymatrine attenuates hepatic steatosis in non-alcoholic fatty liver disease rats fed with high fructose diet through inhibition of sterol regulatory element binding transcription factor 1 (Srebf1) and activation of peroxisome proliferator activated recep
Topics: Alkaloids; Animals; Body Weight; Diet; Dose-Response Relationship, Drug; Dyslipidemias; Energy Intake; Fatty Acids; Fatty Liver; Fructose; Gene Expression Regulation; Liver; Male; Non-alcoholic Fatty Liver Disease; Oxidation-Reduction; PPAR alpha; Quinolizines; Rats; Rats, Wistar; RNA, Messenger; Signal Transduction; Sterol Regulatory Element Binding Protein 1 | 2013 |
Oxymatrine attenuates diabetes-associated cognitive deficits in rats.
Topics: Alkaloids; Animals; Anti-Inflammatory Agents; Antioxidants; Behavior, Animal; Blood Glucose; Body Weight; Caspase 3; Cerebral Cortex; Cognition; Cognition Disorders; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Glutathione; Hippocampus; Inflammation Mediators; Interleukin-1beta; Male; Malondialdehyde; Maze Learning; Memory; Motor Activity; Oxidative Stress; Quinolizines; Rats, Wistar; Streptozocin; Superoxide Dismutase; Time Factors; Transcription Factor RelA; Tumor Necrosis Factor-alpha | 2014 |